SynthesisF1000Research2025
The Efficacy and Safety of SGLT2 Inhibitors in Diabetes Kidney Transplant Recipients: A Systematic Review and Meta-Analysis.
Synthesis in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Insulin Resistance and Atherogenic Dyslipidemia Drive Cardiac Remodeling and Cardiovascular Events After Kidney Transplantation.Journal of clinical medicine · 2026Article
- Post-transplant diabetes mellitus after kidney transplantation: pathogenesis, risk factors, and management strategies.Frontiers in endocrinology · 2026Review
- Metabolic dysregulation and antibody-mediated rejection after kidney transplantation: interacting mechanisms and emerging clinical strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have shown cardiorenal benefits in the general population; however, evidence regarding their efficacy and safety in kidney transplant recipients (KTRs) remains sparse. This meta-analysis seeks to evaluate the therapeutic efficacy and safety profile of SGLT-2 inhibitors specifically in the diabetes KTR population. Methods: We conducted a systemic review and meta-analysis following a registered protocol in the PROSPERO (CRD42023404886). A comprehensive literature search was performed using PubMed, Cochrane, and Scopus databases up to October 23 Results: A total of seven studies comprising 2,713 patients were included in this analysis. SGLT-2 inhibitors were associated with a significant reduction in HbA1c levels (WMD -0.37%; 95% CI -0.73 to -0.01; p = 0.04) and BMI (WMD -0.89 kg/m Conclusions: SGLT-2 inhibitors effectively reduced mortality, cardiovascular disease, HbA1c levels and BMI in KTRs without increasing the risk of infections or allograft rejection. However, they did not demonstrate a significant benefit in kidney-related outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.